T
Treace Medical Concepts
Privately-funded, development stage company focused on bringing breakthrough technologies
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a publicly-traded orthopedic medical device company that operates as a single segment, focusing on the design, manufacturing, and marketing of solutions for the surgical treatment of bunions and related midfoot deformities. The company was founded in 2013 by John T. Treace, a seasoned executive with over 25 years of experience in the medical device industry, who identified a significant opportunity in the foot and ankle market. Drawing on his extensive background, including senior roles at Wright Medical Group and Xomed Surgical Products, Treace assembled a team to address the high dissatisfaction rates associated with traditional bunion surgeries.
The company's business model revolves around selling its patented surgical systems to physicians, surgeons, ambulatory surgery centers, and hospitals, primarily through a direct sales force supplemented by independent distributors. Revenue is generated from the sale of these medical device kits. The company's flagship product is the Lapiplasty® 3D Bunion Correction® System. This system is a comprehensive combination of patented instruments, implants, and surgical methods designed to correct the bunion deformity in all three anatomical planes, thereby addressing the unstable joint considered the root cause of the condition. A key benefit is enabling patients a rapid return to weight-bearing activities in a walking boot. The Lapiplasty system features Biplanar™ plating, which provides robust, multi-planar fixation.
Expanding its portfolio, Treace Medical Concepts also offers the Adductoplasty® System for correcting midfoot deformities that can coexist with bunions, the Hammertoe PEEK Fixation System, and the SpeedPlate™ System for bone fusions. The company went public via an Initial Public Offering (IPO) on the NASDAQ exchange under the ticker symbol "TMCI" on April 23, 2021. This strategic move followed several rounds of funding, including debt financing, to fuel its growth and commercialization efforts. Headquartered in Ponte Vedra, Florida, the company has grown significantly, moving into a new 125,000-square-foot facility in 2022 to accommodate its expanding operations, research, and development activities.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2021
- Outcome tier
- Thoroughbred$100M+ revenue
News
Open roles
Treace Medical Concepts in the Ponte Vedra Beach ecosystem
The Treace Medical Concepts office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
- CLCRG LP
HSBC
SLR Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
87 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Treace Medical Concepts on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Treace Medical Concepts on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

